Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Laura Saint‐Lary"'
Publikováno v:
Pharmacology Research & Perspectives, Vol 12, Iss 4, Pp n/a-n/a (2024)
Abstract In 2018, a significant neural tube defects (NTD) signal was reported after pre‐conceptional exposure to dolutegravir, but was not confirmed in further analysis. Since 2019, dolutegravir‐based regimen, an integrase inhibitor (INI), is rec
Externí odkaz:
https://doaj.org/article/e0686d8f7f394ea38952119baa15d53e
Autor:
Laura Saint-Lary, Justine Benevent, Christine Damase-Michel, Christophe Vayssière, Valériane Leroy, Agnès Sommet
Publikováno v:
BMC Pregnancy and Childbirth, Vol 23, Iss 1, Pp 1-31 (2023)
Background About 1.3 million pregnant women lived with HIV and were eligible to receive antiretroviral therapy (ART) worldwide in 2021. The World Health Organization recommends protease inhibitors (PI)-based regimen as second or third-line during pre
Externí odkaz:
https://doaj.org/article/cbf21e2359394703aa7a1a9003535d9f
Autor:
Laura Saint-Lary, Marc Harris Dassi Tchoupa Revegue, Julie Jesson, Françoise Renaud, Martina Penazzato, Claire L. Townsend, John O'Rourke, Valériane Leroy, WHO HIV Hepatitis and STIs (HHS) Department
Publikováno v:
Frontiers in Pediatrics, Vol 10 (2022)
BackgroundAtazanavir/ritonavir is recommended as a preferred second-line antiretroviral regimen in children older than 3 months, alternatively to lopinavir/ritonavir. We performed a systematic review to assess safety and effectiveness of atazanavir u
Externí odkaz:
https://doaj.org/article/18297fa7b565466eb628c43289b0646d
Autor:
Julie, Jesson, Laura, Saint-Lary, Marc Harris Dassi Tchoupa, Revegue, John, O'Rourke, Claire L, Townsend, Françoise, Renaud, Martina, Penazzato, Valériane, Leroy
Publikováno v:
The Lancet Child & Adolescent Health. 6:692-704
Abacavir is a nucleoside reverse transcriptase inhibitor recommended in paediatric HIV care. We assessed the safety and efficacy profile of abacavir used in first, second, or subsequent lines of treatment for infants, children, and adolescents living
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7dc1c9d1aed7add80969123ed742a95
https://doi.org/10.1016/s2352-4642(22)00213-9
https://doi.org/10.1016/s2352-4642(22)00213-9
Autor:
Vanessa Rousseau, Camille Tisserand, Jasmine Carlier, Jérémie Pariente, Emilie Milongo-Rigal, Marie Benaiteau, Jean-Christophe Pagès, Marie Rafiq, Dominique Gouilly, Leonor Nogueira, Laura Saint-Lary
Publikováno v:
Journal of Alzheimer's Disease. 83:1033-1038
The consistency of cerebrospinal fluid amyloid-β (Aβ)42/40 ratio and Aβ42 has not been assessed in the AT(N) classification system. We analyzed the classification changes of the dichotomized amyloid status (A+/A–) in 363 patients tested for Alzh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09be29a4773df5f5c561be0a0bc10e02
https://doi.org/10.3233/jad-210236
https://doi.org/10.3233/jad-210236
Autor:
Laura Saint-Lary, Justine Benevent, Christine Damase-Michel, Christophe Vayssière, Valériane Leroy, Agnès Sommet
Background: About 1.3 million pregnant women lived with HIV and were eligible to receive antiretroviral therapy (ART) worldwide in 2021. The World Health Organization recommends protease inhibitors (PI)-based regimen as second or third-line during pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32ecebe0d17f277923dbd552d8d69cbd
https://doi.org/10.21203/rs.3.rs-2010098/v1
https://doi.org/10.21203/rs.3.rs-2010098/v1
Autor:
Claire Rekacewicz, Alpha Diallo, Christelle Paul, Agnès Sommet, Roland Tubiana, Albert Faye, Laurent Mandelbrot, Laura Saint-Lary, Jeanne Sibiude, François Dabis, Laure-Amélie de Monteynard, Valériane Leroy, Lucie Marchand, Ventzislava Petrov-Sanchez, Josiane Warszawski
Publikováno v:
British Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology, Wiley, 2021, ⟨10.1111/bcp.15075⟩
British Journal of Clinical Pharmacology, Wiley, 2021, ⟨10.1111/bcp.15075⟩
In 2018, 1.07 million pregnant women received antiretroviral drugs, raising whether this affects pregnancy outcomes. We assessed the adverse pregnancy outcomes associated with prenatal antiretroviral drug exposure, notified to the French ANRS pharmac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::890ea7a30dcefd74010bbad4a3e09039
https://hal.archives-ouvertes.fr/hal-03428753
https://hal.archives-ouvertes.fr/hal-03428753